Product Description: SEM/BSA is an antigen-adjuvant conjugate formed by the conjugation of SEM (furanesalin) with bovine serum albumin (BSA). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Weiss AM, et al. Site-specific antigen-adjuvant conjugation using cell-free protein synthesis enhances antigen presentation and CD8+ T-cell response. Sci Rep. 2021 Mar 18;11(1):6267.